APO RESEARCH · REPORT
Dengue Vaccines
Dengue vaccine is a vaccine used to prevent dengue fever in humans. As of 2019, one version is commercially available, known as CYD-TDV, and sold under the brand name Dengvaxia. The vaccine is only recommended in those who have previously had dengue fever or populations in which most people have been previously infected. The value of the vaccine is limited by the fact that it may worsen outcomes in those who have not previously been infected. It is given as three injections over a year.
Product & engineering
Understand the product.
Dengue vaccine is a vaccine used to prevent dengue fever in humans. As of 2019, one version is commercially available, known as CYD-TDV, and sold under the brand name Dengvaxia. The vaccine is only recommended in those who have previously had dengue fever or populations in which most people have been previously infected. The value of the vaccine is limited by the fact that it may worsen outcomes in those who have not previously been infected. It is given as three injections over a year.
Selected research
Industry Research
Dengue Vaccines Industry Research Report 2026
Market perspective
Dengue vaccine is a vaccine used to prevent dengue fever in humans. As of 2019, one version is commercially available, known as CYD-TDV, and sold under the brand name Dengvaxia. The vaccine is only recommended in those who have previously had dengue fever or populations in which most people have been previously infected. The value of the vaccine is limited by the fact that it may worsen outcomes in those who have not previously been infected. It is given as three injections over a year.
The only one version which is commercially available now, known as Dengvaxia and produced by Sanofi, don't has enough efficacy. While there are several vaccines are on trial now. TAK-003, developed by Takeda is one stride closer to reaching the sizable market waiting for dengue vaccines as it reports positive top-line results from a massive Phase III trial.
Report Scope
Read the full market overview
This report quantifies the global Dengue Vaccines market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Dengue Vaccines.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Dengue Vaccines Market by Company
Sanofi
Takeda
Dengue Vaccines Segment by Type
Dengvaxia
TAK-003
Others
Dengue Vaccines Segment by Application
Public Sector
Private Sector
Dengue Vaccines Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Dengue Vaccines market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Dengue Vaccines and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Dengue Vaccines.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Dengue Vaccines companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Dengvaxia
- TAK-003
- Others
Applications
- Public Sector
- Private Sector
Companies covered
- Sanofi
- Takeda
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Dengue Vaccines by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Dengvaxia
- 2.2.3 TAK-003
- 2.2.4 Others
- 2.3 Dengue Vaccines by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Public Sector
- 2.3.3 Private Sector
- 2.4 Assumptions and Limitations
3 Dengue Vaccines Breakdown Data by Type
- 3.1 Global Dengue Vaccines Historic Market Size by Type (2021-2026)
- 3.2 Global Dengue Vaccines Forecasted Market Size by Type (2027-2032)
4 Dengue Vaccines Breakdown Data by Application
- 4.1 Global Dengue Vaccines Historic Market Size by Application (2021-2026)
- 4.2 Global Dengue Vaccines Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Dengue Vaccines Market Perspective (2021-2032)
- 5.2 Global Dengue Vaccines Growth Trends by Region
- 5.2.1 Global Dengue Vaccines Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Dengue Vaccines Historic Market Size by Region (2021-2026)
- 5.2.3 Dengue Vaccines Forecasted Market Size by Region (2027-2032)
- 5.3 Dengue Vaccines Market Dynamics
- 5.3.1 Dengue Vaccines Industry Trends
- 5.3.2 Dengue Vaccines Market Drivers
- 5.3.3 Dengue Vaccines Market Challenges
- 5.3.4 Dengue Vaccines Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Dengue Vaccines Players by Revenue
- 6.1.1 Global Top Dengue Vaccines Players by Revenue (2021-2026)
- 6.1.2 Global Dengue Vaccines Revenue Market Share by Players (2021-2026)
- 6.2 Global Dengue Vaccines Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Dengue Vaccines Head Office and Area Served
- 6.4 Global Dengue Vaccines Players, Product Type & Application
- 6.5 Global Dengue Vaccines Manufacturers Established Date
- 6.6 Global Dengue Vaccines Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Dengue Vaccines Market Size (2021-2032)
- 7.2 North America Dengue Vaccines Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Dengue Vaccines Market Size by Country (2021-2026)
- 7.4 North America Dengue Vaccines Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Dengue Vaccines Market Size (2021-2032)
- 8.2 Europe Dengue Vaccines Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Dengue Vaccines Market Size by Country (2021-2026)
- 8.4 Europe Dengue Vaccines Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Dengue Vaccines Market Size (2021-2032)
- 9.2 Asia-Pacific Dengue Vaccines Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Dengue Vaccines Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Dengue Vaccines Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Dengue Vaccines Market Size (2021-2032)
- 10.2 South America Dengue Vaccines Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Dengue Vaccines Market Size by Country (2021-2026)
- 10.4 South America Dengue Vaccines Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Dengue Vaccines Market Size (2021-2032)
- 11.2 Middle East & Africa Dengue Vaccines Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Dengue Vaccines Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Dengue Vaccines Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Sanofi
- 12.1.1 Sanofi Company Information
- 12.1.2 Sanofi Business Overview
- 12.1.3 Sanofi Revenue in Dengue Vaccines Business (2021-2026)
- 12.1.4 Sanofi Dengue Vaccines Product Portfolio
- 12.1.5 Sanofi Recent Developments
- 12.2 Takeda
- 12.2.1 Takeda Company Information
- 12.2.2 Takeda Business Overview
- 12.2.3 Takeda Revenue in Dengue Vaccines Business (2021-2026)
- 12.2.4 Takeda Dengue Vaccines Product Portfolio
- 12.2.5 Takeda Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst